Orthocell Ltd
ASX:OCC

Watchlist Manager
Orthocell Ltd Logo
Orthocell Ltd
ASX:OCC
Watchlist
Price: 1.1 AUD 4.76% Market Closed
Market Cap: 298.2m AUD

Intrinsic Value

The intrinsic value of one OCC stock under the Base Case scenario is 0.33 AUD. Compared to the current market price of 1.1 AUD, Orthocell Ltd is Overvalued by 70%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

OCC Intrinsic Value
0.33 AUD
Overvaluation 70%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Orthocell Ltd

What is Valuation History?
Ask AI Assistant
What other research platforms think about OCC?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is OCC valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Orthocell Ltd.

Explain Valuation
Compare OCC to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Orthocell’s lead regenerative platform, CelGro, faces an extended path to widespread adoption due to lingering questions around cost-effectiveness and a need for robust comparative data against established competitors’ regenerative products.

The company’s reliance on future regulatory milestones, particularly in key markets like the U.S. and Europe, adds considerable uncertainty to the near-term revenue outlook and heightens the risk of expensive delays if trials or approvals do not proceed as planned.

Orthocell’s relatively small scale and limited commercial infrastructure may hinder its ability to capture market share against larger, well-capitalized medtech and biotech firms, particularly if it requires aggressive marketing and sales efforts to win surgeon and hospital adoption.

Bull Theses

CelGro’s potential to address multiple indications—nerve, bone, tendon, and soft tissue repair—positions Orthocell for significant long-term growth if positive clinical results continue and the platform gains broader reimbursement support.

Orthocell’s focused R&D strategy has produced early clinical successes, such as promising outcomes in dental and nerve regeneration, which could establish the company as a leader in the niche of collagen-based regenerative scaffolds, attracting licensing or acquisition interest from larger players.

The company’s methodical approach to collaboration, including partnerships with research institutions and medical specialists, sets a foundation for peer-reviewed evidence and strong surgeon buy-in, which could accelerate CelGro’s market acceptance and fuel international expansion.

Show More Less
How do you feel about OCC?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Orthocell Ltd

Current Assets 31.8m
Cash & Short-Term Investments 28.6m
Receivables 1.8m
Other Current Assets 1.4m
Non-Current Assets 3.4m
PP&E 2.3m
Intangibles 1.1m
Other Non-Current Assets -100
Current Liabilities 6.4m
Accounts Payable 2.2m
Accrued Liabilities 1.7m
Other Current Liabilities 2.5m
Non-Current Liabilities 14.3m
Long-Term Debt 411.6k
Other Non-Current Liabilities 13.9m
Efficiency

Free Cash Flow Analysis
Orthocell Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Orthocell Ltd

Revenue
9.2m AUD
Cost of Revenue
-2.7m AUD
Gross Profit
6.5m AUD
Operating Expenses
-18.2m AUD
Operating Income
-11.8m AUD
Other Expenses
3.2m AUD
Net Income
-8.6m AUD
Fundamental Scores

OCC Profitability Score
Profitability Due Diligence

Orthocell Ltd's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin
Strong 3Y Average Gross Margin
Operating Margin is Increasing
Net Margin is Increasing
19/100
Profitability
Score

Orthocell Ltd's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

OCC Solvency Score
Solvency Due Diligence

Orthocell Ltd's solvency score is 94/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Short-Term Solvency
Negative Net Debt
94/100
Solvency
Score

Orthocell Ltd's solvency score is 94/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

OCC Price Targets Summary
Orthocell Ltd

Wall Street analysts forecast OCC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for OCC is 1.36 AUD with a low forecast of 1.34 AUD and a high forecast of 1.4 AUD.

Lowest
Price Target
1.34 AUD
22% Upside
Average
Price Target
1.36 AUD
23% Upside
Highest
Price Target
1.4 AUD
27% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Orthocell Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for OCC is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one OCC stock?

The intrinsic value of one OCC stock under the Base Case scenario is 0.33 AUD.

Is OCC stock undervalued or overvalued?

Compared to the current market price of 1.1 AUD, Orthocell Ltd is Overvalued by 70%.

Back to Top